A Phase I Open Label Study of E7974 Administered on a Day 1 of 21-Day Cycle In Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of E7974 after
bolus IV administration, on Day 1 of a 21-day cycle, to patients with advanced solid tumors
that have progressed following effective therapy or for which no effective therapy exists.